Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer
Open Access
- 13 December 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (24) , 6367-6382
Abstract
Purpose: The study of the cancer secretome suggests that a fraction of the intracellular proteome could play unanticipated roles in the extracellular space during tumorigenesis. A project aimed at investigating the invasive secretome led us to study the alternative extracellular function of the nuclear protein high mobility group A1 (HMGA1) in breast cancer invasion and metastasis. Experimental Design: Antibodies against HMGA1 were tested in signaling, adhesion, migration, invasion, and metastasis assays using breast cancer cell lines and xenograft models. Fluorescence microscopy was used to determine the subcellular localization of HMGA1 in cell lines, xenograft, and patient-derived xenograft models. A cohort of triple-negative breast cancer (TNBC) patients was used to study the correlation between subcellular localization of HMGA1 and the incidence of metastasis. Results: Our data show that treatment of invasive cells with HMGA1-blocking antibodies in the extracellular space impairs their migration and invasion abilities. We also prove that extracellular HMGA1 (eHMGA1) becomes a ligand for the Advanced glycosylation end product-specific receptor (RAGE), inducing pERK signaling and increasing migration and invasion. Using the cytoplasmic localization of HMGA1 as a surrogate marker of secretion, we showed that eHMGA1 correlates with the incidence of metastasis in a cohort of TNBC patients. Furthermore, we show that HMGA1 is enriched in the cytoplasm of tumor cells at the invasive front of primary tumors and in metastatic lesions in xenograft models. Conclusions: Our results strongly suggest that eHMGA1 could become a novel drug target in metastatic TNBC and a biomarker predicting the onset of distant metastasis.Keywords
All Related Versions
Funding Information
- Instituto Salud Carlos III (FIS PI15/00357)
- Federación Española de Enfermedades Raras (CCR15333737)
- Breast Cancer Research Foundation (BCRF-17-008)
- Instituto de Salud Carlos III (PI16/00253)
- Fundació la Marató de TV3 (337/C/2013)
- Society of Gastrointestinal Radiologists (2014 SGR 1394)
This publication has 50 references indexed in Scilit:
- The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer contextBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2013
- HMGA1: A Master Regulator of Tumor Progression in Triple-Negative Breast Cancer CellsPLOS ONE, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Batch effects correction improves the sensitivity of significance tests in spectral counting-based comparative discovery proteomicsJournal of Proteomics, 2012
- The Unconventional Secretory Machinery of Fibroblast Growth Factor 2Traffic, 2011
- Knock down of HIF-1α in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheresMolecular Cancer, 2010
- High-Mobility Group A (HMGA) Proteins and Breast CancerBreast Care, 2010
- HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinomaLaboratory Investigation, 2010
- High mobility group AT‐hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinomaCancer, 2008
- The DEK Nuclear Autoantigen Is a Secreted Chemotactic FactorMolecular and Cellular Biology, 2006